In the past year, shares of Halozyme have rallied 65.8% against the industry’s decline of 3.5%. Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.64; value investors ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. HALO has a Growth Style Score of B, forecasting year-over-year ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Momentum investors should take note of this Medical stock. HALO has a Momentum Style Score of A, and shares are up 15.9% over the past ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.37; value investors ...

HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Additionally, the company could be a top pick for growth investors. HALO has a Growth Style Score of B, forecasting year-over-year ...

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

In the preceding three months, 8 analysts have released ratings for Halozyme Therapeutics (NASDAQ:HALO), presenting a wide ... Therapeutics's financials over 3 months reveals a positive narrative.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They ...

NASDAQ HALO opened at $58.29 on Friday ... The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business’s 50-day simple moving average ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce ...